

CITATION REPORT

List of articles citing

Clinical pharmacokinetics of losartan

DOI: 10.2165/00003088-200544080-00003
Clinical Pharmacokinetics, 2005, 44, 797-814.

Source: <https://exaly.com/paper-pdf/39421306/citation-report.pdf>

Version: 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
163	Losartan: a review of its use in stroke risk reduction in patients with hypertension and left ventricular hypertrophy. 2005 , 65, 2657-74		16
162	Drug-induced changes in P450 enzyme expression at the gene expression level: a new dimension to the analysis of drug-drug interactions. 2006 , 36, 1013-80		24
161	Angiotensin receptor blockers: new considerations in their mechanism of action. 2006 , 8, 381-5		8
160	The Renin Report. 2006 , 7, 247-51		3
159	Validated quantitation of angiotensin II receptor antagonists (ARA-II) in human plasma by liquid-chromatography-tandem mass spectrometry using minimum sample clean-up and investigation of ion suppression. 2007 , 29, 824-34		34
158	Pharmacokinetics, safety, and tolerability of the oral Renin inhibitor aliskiren in patients with hepatic impairment. 2007 , 47, 192-200		46
157	Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol. <i>Clinical Pharmacokinetics</i> , 2007 , 46, 623-44	6.2	117
156	Losartan and its interaction with copper(II): biological effects. 2007 , 15, 6418-24		24
155	Separation and quantitation of several angiotensin II receptor antagonist drugs in human urine by a SPE-HPLC-DAD method. 2008 , 31, 667-76		26
154	Do drugs that block transforming growth factor beta reduce posthaemorrhagic ventricular dilatation in a neonatal rat model?. 2008 , 97, 1181-6		25
153	Antihypertensive drugs. 2008 , 234-251		
152	Losartan metabolite EXP3179: an AT1-receptor-independent treatment strategy for patients with the metabolic syndrome?. 2009 , 54, 710-2		11
151	Effect of soy extract administration on losartan pharmacokinetics in healthy female volunteers. 2009 , 43, 1045-9		12
150	Simultaneous quantification of losartan and active metabolite in human plasma by liquid chromatography-tandem mass spectrometry using irbesartan as internal standard. 2009 , 49, 862-7		32
149	Bioequivalence model for evaluation of Losartan in human plasma with special reference to drug metabolite ratio. 2009 , 26, 101-112		4
148	Renin-Angiotensin Blockade: Therapeutic Agents. 2009 , 189-201		1
147	Simultaneous determination of losartan and hydrochlorothiazide in human plasma by LC/MS/MS with electrospray ionization and its application to pharmacokinetics. <i>Clinical and Experimental Hypertension</i> , 2009 , 31, 415-27	2.2	18

146	In vitro screening of 50 highly prescribed drugs for thiol adduct formation--comparison of potential for drug-induced toxicity and extent of adduct formation. 2009 , 22, 690-8		82
145	Rationale and design of a trial evaluating the effects of losartan vs. nebivolol vs. the association of both on the progression of aortic root dilation in Marfan syndrome with FBN1 gene mutations. 2009 , 10, 354-62		56
144	Inhibition of the renin-angiotensin system prevents seizures in a rat model of epilepsy. 2010 , 119, 477-82		56
143	Development of swelling/floating gastroretentive drug delivery system based on a combination of hydroxyethyl cellulose and sodium carboxymethyl cellulose for Losartan and its clinical relevance in healthy volunteers with CYP2C9 polymorphism. 2010 , 39, 82-9		55
142	Issues in drug metabolism of major antihypertensive drugs: beta-blockers, calcium channel antagonists and angiotensin receptor blockers. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2010 , 6, 199-211	5.5	19
141	Pharmacokinetic evaluation of losartan. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2011 , 7, 643-9.5		18
140	Increasing Lipophilicity for Oral Drug Delivery. 2011 , 79-109		
139	Prodrugs--from serendipity to rational design. 2011 , 63, 750-71		349
138	Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors. 2011 , 108, 2909-14		455
137	Effect of age on the pharmacokinetics of fimasartan (BR-A-657). <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2011 , 7, 1337-44	5.5	21
136	ADME of Cardiovascular Drugs. 2012 , 1		
135	Characterization of the in vivo antiplatelet activity of the antihypertensive agent losartan. 2012 , 17, 308-14		11
134	Comparison of the efficacy and safety of fixed-dose amlodipine/losartan and losartan in hypertensive patients inadequately controlled with losartan: a randomized, double-blind, multicenter study. 2012 , 12, 189-95		13
133	The pharmacokinetics and pharmacodynamics of valsartan in the post-myocardial infarction population. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2012 , 8, 1469-82	5.5	2
132	Simultaneous determination of losartan, losartan acid and amlodipine in human plasma by LC-MS/MS and its application to a human pharmacokinetic study. 2012 , 3, 18-25		20
131	Evaluation of water uptake and mechanical properties of blended polymer films for preparing gas-generated multiple-unit floating drug delivery systems. 2012 , 101, 3811-22		6
130	Pharmacokinetics of losartan and its active carboxylic acid metabolite E-3174 in five ethnic populations of China. 2012 , 37, 226-31		11
129	Physical characterizations and sustained release profiling of gastroretentive drug delivery systems with improved floating and swelling capabilities. 2013 , 441, 162-9		32

128	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers. 2013 , 41, 224-9		36
127	A 26-week repeated-dose toxicity study of allisartan isoproxil in Sprague-Dawley rats. 2013 , 36, 443-50		4
126	Characterizations of plasticized polymeric film coatings for preparing multiple-unit floating drug delivery systems (muFDDSs) with controlled-release characteristics. 2014 , 9, e100321		12
125	Clinical pharmacokinetics of drugs in patients with heart failure: an update (part 2, drugs administered orally). <i>Clinical Pharmacokinetics</i> , 2014 , 53, 1083-114	6.2	40
124	Evaluation of felodipine as a potential perpetrator of pharmacokinetic drug-drug interactions. 2014 , 70, 1115-22		16
123	Direct C-N coupling of imidazoles with aromatic and benzylic compounds via Electrooxidative C-H functionalization. 2014 , 136, 4496-9		144
122	Multicomponent synthesis of substituted and fused-ring imidazoles via phosphamethylenone cycloaddition. 2015 , 80, 2709-14		25
121	Losartan: Comprehensive Profile. 2015 , 40, 159-94		22
120	Differences in CYP2C9 Genotype and Enzyme Activity Between Swedes and Koreans of Relevance for Personalized Medicine: Role of Ethnicity, Genotype, Smoking, Age, and Sex. 2015 , 19, 346-53		16
119	Modeling the effects of commonly used drugs on human metabolism. 2015 , 282, 297-317		25
118	A new spectrofluorimetric method for determination of losartan potassium in rabbit plasma and its application to pharmacokinetic study. 2015 , 30, 53-9		5
117	Losartan. 2016 , 687-692		
116	Comparisons of the pharmacokinetics and tolerability of fixed-dose combinations of amlodipine besylate/losartan and amlodipine camsylate/losartan in healthy subjects: a randomized, open-label, single-dose, two-period, two-sequence crossover study. 2016 , 10, 3021-3028		4
115	In vitro inhibition of cytochrome P-450 activities and quantification of constituents in a selection of commercial <i>Rhodiola rosea</i> products. 2016 , 54, 3249-3256		13
114	PK/PD interaction study of angiotensin II antagonist, losartan, with selective estrogen receptor modulator, centchroman. 2016 , 1, 17-23		1
113	Effect of fermented red ginseng on cytochrome P450 and P-glycoprotein activity in healthy subjects, as evaluated using the cocktail approach. <i>British Journal of Clinical Pharmacology</i> , 2016 , 82, 1580-1590	3.8	23
112	Pharmacogenetic approach to losartan in Marfan patients: a starting point to improve dosing regimen?. 2016 , 31, 157-63		4
111	Functioning of drug-metabolizing microsomal cytochrome P450s: In silico probing of proteins suggests that the distal heme active site pocket plays a relatively passive role in some enzyme-substrate interactions. 2016 , 4, 2		16

110	Evidence to Consider Angiotensin II Receptor Blockers for the Treatment of Early Alzheimer's Disease. 2016 , 36, 259-79	54
109	Strategies in the designing of prodrugs, taking into account the antiviral and anticancer compounds. 2017 , 129, 53-71	18
108	Prediction of Losartan-Active Carboxylic Acid Metabolite Exposure Following Losartan Administration Using Static and Physiologically Based Pharmacokinetic Models. 2017 , 106, 2758-2770	9
107	Impact of Probe Substrate Selection on Cytochrome P450 Reaction Phenotyping Using the Relative Activity Factor. 2017 , 45, 183-189	12
106	Structural Basis of Single-Nucleotide Polymorphisms in Cytochrome P450 2C9. 2017 , 56, 5476-5480	33
105	Intrarenal Mas and AT receptors play a role in mediating the excretory actions of renal interstitial angiotensin-(1-7) infusion in anaesthetized rats. 2017 , 102, 1700-1715	8
104	Regulating cancer associated fibroblasts with losartan-loaded injectable peptide hydrogel to potentiate chemotherapy in inhibiting growth and lung metastasis of triple negative breast cancer. 2017 , 144, 60-72	81
103	A statistical study on the development of micro particulate sustained drug delivery system for Losartan potassium by 3 2 factorial design approach. 2017 , 55, 19-29	11
102	Complex formation equilibria of Cu and Zn with Irbesartan and Losartan. 2017 , 97, 158-169	6
101	A clean photometric method for the determination of losartan potassium in pharmaceuticals exploiting light scattering effect and employing a multicommuted flow analysis approach. 2017 , 164, 183-188	5
100	The Role of Cyclooxygenase Enzymes in the Effects of Losartan and Lisinopril on the Contractions of Rat Thoracic Aorta. 2017 , 49, 16-21	1
99	Validated determination of losartan and valsartan in human plasma by stir bar sorptive extraction based on acrylate monolithic polymer, liquid chromatographic analysis and experimental design methodology. 2018 , 153, 204-213	27
98	Role of cytochrome P450 enzymes in fimasartan metabolism in vitro. 2018 , 115, 375-384	2
97	Multicomponent reactions: a sustainable tool to 1,2- and 1,3-azoles. 2018 , 16, 9084-9116	27
96	Renin-Angiotensin Blockade: Therapeutic Agents. 2018 , 57-75	
95	Integrating theoretical and experimental permeability estimations for provisional biopharmaceutical classification: Application to the WHO essential medicines. 2018 , 39, 354-368	8
94	Tumor targeting via EPR: Strategies to enhance patient responses. 2018 , 130, 17-38	618
93	Human Extinction Learning Is Accelerated by an Angiotensin Antagonist via Ventromedial Prefrontal Cortex and Its Connections With Basolateral Amygdala. 2019 , 86, 910-920	12

92	Pharmacokinetic and haemodynamic interactions between amlodipine and losartan in human beings. 2019 , 125, 345-352		4
91	Hydroxyl Groups in Synthetic and Natural-Product-Derived Therapeutics: A Perspective on a Common Functional Group. 2019 , 62, 8915-8930		36
90	Celiprolol but not losartan improves the biomechanical integrity of the aorta in a mouse model of vascular Ehlers-Danlos syndrome. 2020 , 116, 457-465		15
89	Predictive Value of Microdose Pharmacokinetics. <i>Clinical Pharmacokinetics</i> , 2019 , 58, 1221-1236	6.2	6
88	Pharmacokinetic and pharmacodynamic considerations in the treatment of the elderly patient with hypertension. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2019 , 15, 287-297	5.5	6
87	Angiotensin II Type I Receptor Blockade Is Associated with Decreased Cutaneous Scar Formation in a Rat Model. 2019 , 144, 803e-813e		8
86	Modelling gastric emptying: A pharmacokinetic model simultaneously describing distribution of losartan and its active metabolite EXP-3174. 2020 , 126, 193-202		5
85	Clinical Validation of a Dried Blood Spot Assay for 8 Antihypertensive Drugs and 4 Active Metabolites. 2020 , 42, 460-467		8
84	Simultaneous Determination of Losartan and Rosuvastatin in Rat Plasma Using Liquid Chromatography Tandem Mass Spectrometric Technique for Application into Pharmacokinetic and Drug-Drug Interaction Studies. 2020 , 83, 1477-1494		7
83	Development and Characterization of Starch/Gelatin Microneedle Arrays Loaded with Lecithin-Gelatin Nanoparticles of Losartan for Transdermal Delivery. 2020 , 1		6
82	A perspective on potential target proteins of COVID-19: Comparison with SARS-CoV for designing new small molecules. 2020 , 104, 104326		12
81	Safety perspectives on presently considered drugs for the treatment of COVID-19. 2020 , 177, 4353-4374		9
80	Vancomycin-induced hypokalemia: A proof-of-concept case report. 2020 , 510, 232-234		2
79	Structure of Cytochrome P450 2C9*2 in Complex with Losartan: Insights into the Effect of Genetic Polymorphism. 2020 , 98, 529-539		2
78	Medications for Hypertension Change the Secretome Profile from Marrow Stromal Cells and Peripheral Blood Monocytes. 2020 , 2020, 8894168		1
77	HPMC/Carbopol based extended release gastroretentive dosage form of losartan potassium: Formulation and in vivo pharmacokinetic evaluation in rabbits. 2020 , 60, 102006		0
76	Continuous-flow photo-induced decarboxylative annulative access to fused imidazole derivatives via a microreactor containing immobilized ruthenium. 2020 , 22, 1565-1571		10
75	Comparison of Pharmacokinetics of a Fixed-Dose Combination of Amlodipine/Losartan/Rosuvastatin with Concomitant Administration of Amlodipine/Losartan and Rosuvastatin in Healthy Volunteers. 2020 , 14, 661-668		1

74	Added Value of Clinical Sequencing: WGS-Based Profiling of Pharmacogenes. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	16
73	IDentif.AI: Rapidly optimizing combination therapy design against severe Acute Respiratory Syndrome Coronavirus 2 (SARS-Cov-2) with digital drug development. 2021 , 6, e10196		9
72	Ongoing Clinical Trials and the Potential Therapeutics for COVID-19 Treatment. 2021 , 27-89		
71	Angiotensin II Type 1 Receptor Antagonist Losartan Inhibits TNF- α -Induced Inflammation and Degeneration Processes in Human Nucleus Pulposus Cells. 2021 , 11, 417		0
70	Effect of CYP2C9 genetic polymorphism and breviscapine on losartan pharmacokinetics in healthy subjects. 2021 , 51, 616-623		3
69	Investigating the Impact of Gastric Emptying on Pharmacokinetic Parameters Using Delay Differential Equations and Principal Component Analysis. 2021 , 46, 451-458		
68	Pharmacogenomics of hypertension in chronic kidney disease: the CKD-PGX study.		
67	Principles of Drug Metabolism. 1-139		
66	Ullmann-Goldberg and Buchwald-Hartwig C-N Cross Couplings: Synthetic Methods to Pharmaceutically Potential N-Heterocycles. 2021 , 10, 1319-1344		17
65	Design, synthesis and antihypertensive evaluation of novel codrugs with combined angiotensin type 1 receptor antagonism and neprilysin inhibition. 2021 , 159, 105731		0
64	Preparation of amine-modified lignin and its applicability toward online micro-solid phase extraction of valsartan and losartan in urine samples. 2021 , 1643, 462081		2
63	Allisartan isoproxil reduces mortality of stroke-prone rats and protects against cerebrovascular, cardiac, and aortic damage. <i>Acta Pharmacologica Sinica</i> , 2021 , 42, 871-884	8	1
62	Drug metabolism in severe chronic obstructive pulmonary disease: A phenotyping cocktail study. <i>British Journal of Clinical Pharmacology</i> , 2021 , 87, 4397-4407	3.8	
61	Amlodipine interfere in serum albumin binding of losartan and its active metabolite losartan carboxylic acid (EXP- 1734): Contra-contemporary in vitro approaches. <i>Analytical Chemistry Letters</i> , 2021 , 11, 376-391	1	
60	Han Chinese specific cytochrome P450 polymorphisms and their impact on the metabolism of anti-hypertensive drugs with adrenoreceptor blocking properties. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2021 , 17, 707-716	5.5	0
59	Allisartan ameliorates vascular remodeling through regulation of voltage-gated potassium channels in hypertensive rats. <i>BMC Pharmacology & Toxicology</i> , 2021 , 22, 33	2.6	
58	Measuring and modeling the solubility of an antihypertensive drug (losartan potassium, Cozaar) in supercritical carbon dioxide. <i>Journal of Molecular Liquids</i> , 2021 , 331, 115745	6	7
57	Pre-clinical drug-drug interaction (DDI) of gefitinib or erlotinib with Cytochrome P450 (CYP) inhibiting drugs, fluoxetine and/or losartan. <i>Current Research in Toxicology</i> , 2021 , 2, 217-224	2.7	0

56	Pharmacokinetics of a Fixed-Dose Combination of Amlodipine/Losartan and Chlorthalidone Compared to Concurrent Administration of the Separate Components. <i>Clinical Pharmacology in Drug Development</i> , 2021 ,	2.3	
55	Determination of Thermodynamics Constant of Interaction among of Atenolol and Metoprolol with Human Serum Albumin: Spectroscopic and Molecular Modeling Approaches. <i>Russian Journal of Physical Chemistry A</i> , 2021 , 95, 1269-1276	0.7	1
54	A multi-center phase II randomized clinical trial of losartan on symptomatic outpatients with COVID-19. <i>EclinicalMedicine</i> , 2021 , 37, 100957	11.3	21
53	Solid Dispersion: A Mechanistic and Realistic Approach on Antihypertensive Drug as a Drug Carrier System. <i>Assay and Drug Development Technologies</i> , 2021 , 19, 282-289	2.1	1
52	The angiotensin antagonist Losartan shifts social reward motivation and punishment feedback sensitivity via modulating midbrain-striato-frontal circuits.		0
51	Modulation of the renin-angiotensin system inhibits memory advantage for negative emotional material via decreasing hippocampus activation and its coupling with the amygdala.		0
50	Effect of losartan on hospitalized patients with COVID-19-induced lung injury: A randomized clinical trial.		3
49	Ecotoxicity of losartan potassium in aquatic organisms of different trophic levels. <i>Environmental Toxicology and Pharmacology</i> , 2021 , 87, 103727	5.8	1
48	Prediction of potential drug interactions between repurposed COVID-19 and antitubercular drugs: an integrational approach of drug information software and computational techniques data. <i>Therapeutic Advances in Drug Safety</i> , 2021 , 12, 20420986211041277	3.5	0
47	Effect of laparoscopic sleeve gastrectomy on drug pharmacokinetics. <i>Expert Review of Clinical Pharmacology</i> , 2021 , 1-15	3.8	0
46	Drugs Used to Treat Hypertension, Heart Failure, and Angina Pectoris. 2009 , 1-196		
45	Mathematical Modeling of the Antihypertensive Drugs Action. <i>Mathematical Biology and Bioinformatics</i> , 2019 , 14, 233-256	0.5	
44	Herb-Drug Interaction of Quercetin on the Pharmacokinetics of Losartan in Rats: A High-Performance Thin-Layer Chromatography Study. <i>Journal of Planar Chromatography - Modern TLC</i> , 2019 , 32, 401-409	0.9	
43	Clinical pharmacogenetics of angiotensin II receptor blockers. <i>Farmakogenetika I Farmakogenomika</i> , 2020 , 19-25	0.2	
42	New Analytical Method for Simultaneous Analysis of Losartan and E-3174 by HPLC in Human Plasma: Application in Pharmaceutical Science. <i>Current Analytical Chemistry</i> , 2020 , 16, 979-987	1.7	
41	Voluntary Oral Administration of Losartan in Rats. <i>Journal of the American Association for Laboratory Animal Science</i> , 2015 , 54, 549-56	1.3	14
40	Association of losartan with outcomes in metastatic pancreatic cancer patients treated with chemotherapy. <i>Journal of Clinical and Translational Research</i> , 2021 , 7, 257-262	1.1	
39	Effect of allisartan on blood pressure and left ventricular hypertrophy through Kv1.5 channels in hypertensive rats.. <i>Clinical and Experimental Hypertension</i> , 2022 , 1-9	2.2	

38	Prediction of CYP-mediated silybin A-losartan pharmacokinetic interactions using physiological based pharmacokinetic modeling.. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2022 , 1	2.7	0
37	Phytomedicine as a source of SGLT2 inhibitors, GLP-1 secretagogues and DPP-IV inhibitors for mitigation of Diabetic Nephropathy. <i>Phytomedicine Plus</i> , 2022 , 2, 100225		
36	Pleiotropic Effects of Simvastatin and Losartan in Preclinical Models of Post-Traumatic Elbow Contracture.. <i>Frontiers in Bioengineering and Biotechnology</i> , 2022 , 10, 803403	5.8	
35	Efficacy of Losartan in Hospitalized Patients With COVID-19-Induced Lung Injury: A Randomized Clinical Trial.. <i>JAMA Network Open</i> , 2022 , 5, e222735	10.4	10
34	Angiotensin blockade enhances motivational reward learning via enhancing ventral striatal prediction error and frontostriatal communication.		0
33	Personalized pharmacotherapy of arterial hypertension patients with musculoskeletal system diseases based on pharmacogenetic aspects. <i>Farmakogenetika I Farmakogenomika</i> , 2022 , 24-32	0.2	
32	Pharmacogenomics of Hypertension in CKD: The CKD-PGX Study.. <i>Kidney360</i> , 2022 , 3, 307-316	1.8	2
31	Evaluation of Potential Herb-Drug Interactions Between Shengmai Injection and Losartan Potassium in Rat and .. <i>Frontiers in Pharmacology</i> , 2022 , 13, 878526	5.6	2
30	Comparison of Losartan and Furosemide Interaction with HSA and Their Influence on HSA Antioxidant Potential. <i>Pharmaceuticals</i> , 2022 , 15, 499	5.2	0
29	Givosiran Likely Inhibits Cytochrome P450 More Substantially Than Reported.. <i>Clinical Pharmacology and Therapeutics</i> , 2022 ,	6.1	0
28	Elevated TGFβ signaling contributes to ocular anterior segment dysgenesis in Col4a1 mutant mice.. <i>Matrix Biology</i> , 2022 ,	11.4	0
27	Angiotensin antagonist inhibits preferential negative memory encoding via decreasing hippocampus activation and its coupling with amygdala. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2022 ,	3.4	0
26	Therapeutic Potential of Pretreatment with Exosomes Derived from Stem Cells from the Apical Papilla against Cisplatin-Induced Acute Kidney Injury. <i>International Journal of Molecular Sciences</i> , 2022 , 23, 5721	6.3	1
25	Occurrence and removal of drugs and endocrine disruptors in water supply systems in the metropolitan region of Belo Horizonte (Minas Gerais State, Brazil). <i>Environmental Monitoring and Assessment</i> , 2022 , 194,	3.1	
24	Patient-derived microphysiological model identifies the therapeutic potential of metformin for thoracic aortic aneurysm. <i>EBioMedicine</i> , 2022 , 81, 104080	8.8	0
23	Pre-clinical drug-drug interactions (DDIs) of gefitinib with/without losartan and selective serotonin reuptake inhibitors (SSRIs): citalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, and venlafaxine. <i>Current Research in Pharmacology and Drug Discovery</i> , 2022 , 3, 100112	3	0
22	In Vitro Identification of Potential Metabolites of Plinabulin (NPI 2358) in Hepatic Preparations Using Liquid Chromatography on Trap Mass Spectrometry. <i>ACS Omega</i> ,	3.9	
21	Formulation and Pharmacokinetic Evaluation of Ethyl Cellulose/HPMC-Based Oral Expandable Sustained Release Dosage of Losartan Potassium. <i>AAPS PharmSciTech</i> , 2022 , 23,	3.9	

20	Dysregulated myosin in Hermansky-Pudlak syndrome lung fibroblasts is associated with increased cell motility. <i>Respiratory Research</i> , 2022 , 23,	7.3	○
19	Preparation and In Vitro Evaluation of Controlled-Release Matrices of Losartan Potassium Using Ethocel Grade 10 and Carbopol 934P NF as Rate-Controlling Polymers. <i>Polymers</i> , 2022 , 14, 2993	4.5	○
18	Inhibition of the Renin-Angiotensin System Fails to Suppress β Aminopropionitrile-Induced Thoracic Aortopathy in Mice.		
17	Angiotensin blockade enhances motivational reward learning via enhancing striatal prediction error signaling and frontostriatal communication.		○
16	Magic Bullets: The Coming Age of Meaningful Pharmacological Control of the Corneal Responses to Injury and Disease.		1
15	Losartan metabolite EXP3179 is a unique blood pressure-lowering AT1R antagonist with direct, rapid endothelium-dependent vasoactive properties. 2022 , 107112		○
14	Advancement and Authentication of Spectrophotometric Method for Detection of Losartan Potassium.		○
13	Angiotensin II regulates the neural expression of subjective fear in humans - precision pharmaco-neuroimaging approach. 2022 ,		○
12	Therapeutic Drug Monitoring and Toxicology: Relevance of Measuring Metabolites. 2022 , 197-232		○
11	Intradermal delivery of an angiotensin II receptor blocker using a personalized microneedle patch for treatment of hypertrophic scars.		○
10	Effectiveness of losartan on infrapatellar fat pad/synovial fibrosis and pain behavior in the monoiodoacetate-induced rat model of osteoarthritis pain. 2023 , 158, 114121		○
9	Synthesis of Fully Substituted 5-(o-Hydroxybenzoyl)imidazoles via Iodine-Promoted Domino Reaction of Aurones with Amidines. 2022 , 87, 16204-16212		2
8	The angiotensin antagonist Losartan modulates social reward motivation and punishment sensitivity via modulating midbrain-striato-frontal circuits. JN-RM-1114-22		○
7	Mathematical modeling of antihypertensive therapy. 13,		○
6	CYP2C9 gene polymorphisms influence on antihypertensive effectiveness and hypouricemic effect of losartan among patients with arterial hypertension: an observational study. 2022 ,		○
5	The effects of losartan or angiotensin II receptor antagonists on cartilage: a systematic review. 2022 ,		○
4	Changes in Pharmacokinetics and Pharmacodynamics of Losartan in Experimental Diseased Rats Treated with Curcuma longa and Lepidium sativum. 2023 , 16, 33		○
3	Angiotensin blockade enhances motivational reward learning via enhancing striatal prediction error signaling and frontostriatal communication.		○

- 2 AT1 receptor downregulation: A mechanism for improving glucose homeostasis. 14, 170-178 ○
- 1 The central renin angiotensin II system β genetic pathway, functional decoding and selective target engagement characterization in humans. ○